A simple and portable device for the quantification of TNF-α in human plasma by means of on-chip magnetic bead-based proximity ligation assay
| Autor: | Vanessa Castro-López, Marcin Pacek, Luis Bujanda, Elizabeth Hijona, Jorge Elizalde |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Materials science
Tumor Necrosis Factor-alpha Point-of-care testing Point-of-Care Systems Biomedical Engineering Biophysics Nanotechnology General Medicine Proximity ligation assay Biosensing Techniques Equipment Design Microfluidic Analytical Techniques Real-Time Polymerase Chain Reaction 3. Good health Central laboratory Sample volume Microfluidic chip Human plasma Limit of Detection Magnetic bead Electrochemistry Humans Biotechnology Point of care Biomedical engineering |
| Zdroj: | Biosensorsbioelectronics. 54 |
| ISSN: | 1873-4235 |
| Popis: | There is a general need in healthcare systems all around the world to reduce costs in terms of time and money without compromising patients outcome. Point-of-Care Testing (POCT) is currently being used in some applications (e.g. POC coagulation devices) as an alternative to already established standard central laboratory tests to overcome sample transportation and long turnaround times. The main objective of this investigation was to quantify Tumour Necrosis Factor-alpha (TNF-α) on-chip within the clinical relevant range of 5-100 pg/mL in human pooled plasma. The novel solid-phase assay developed in this study was a magnetic bead-based proximity ligation assay (PLA) in which one of the assay proximity probes was directly immobilised onto streptavidin-coated magnetic beads. The portable device was based on a disposable and single-use cyclo-olefin polymer (COP) microfluidic chip interfaced with a quantitative real-time polymerase chain reaction (qPCR) device previously developed in-house. Sample volume was 10 µL and total assay time under 3 h. The POC device and assay developed offer portability, smaller reagent and sample consumption, and faster time-to-results compared with standard ELISAs. Determination and monitoring of TNF-α therapy at the point-of-care will help to improve clinical and/or economical outcome in governmental healthcare budgets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect